Neuralink announces its first clinical trial in humans, promises to connect brains and computers

Elon Musk's Neuralink Takes the Step into Human Clinical Trials


Neuralink, the innovative biotech company founded by Elon Musk, has officially started the Recruitment process to conduct your first clinical trial in humans. This news comes after the company received the go-ahead from an independent review committee.

The study, called PRIME (Precise Robotically Implanted Brain-Computer Interface), It aims to evaluate both the safety and functionality of the brain implant. Patients with conditions such as quadriplegia to cause of cervical spinal cord injury or lateral sclerosis Amyotrophic women (ALS) will be candidates for this six-year trial. The process will include 18 months of clinical follow-up and Home review, followed by five years of reviews.

Through a robot, a chip will be surgically implanted in the brain region responsible for the desire for movement. This chip will capture and It will transmit brain signals to an app. The main purpose is Provide patients with the ability to manipulate a cursor or keyboard computer using exclusively your thoughts.

While Neuralink's vision is revolutionary, it has not been without itself. of controversies. Prior to these human trials, the tests were had been carried out on animals, and there was one prominent incident in 2022. where a monkey died during an experiment related to the video game Pong. It has also faced concerns and scrutiny. security-related, particularly with possible displacement of the implant and damage to brain tissue.

Author Walter Isaacson, in his recent book on Neuralink, mentions that Musk found inspiration in science fiction writers such as Iain Banks. His vision is to develop a "neural socket" that connects Directly human thoughts to a computer.

Recently, Neuralink announced that the FDA has given them the green light to take conducted human trials. This announcement came shortly after the The company will raise $280 million in funding, backed by Peter Thiel's Founders Fund.

Elon Musk, on his social network X (formerly Twitter), expressed his enthusiasm about Neuralink's future developments. Although Musk has been optimistic about Neuralink's progress since 2019, FDA He initially rejected his proposal in 2022 due to concerns of safety.

It is essential to note that before Neuralink products are available to the general public, must be approved by regulatory entities. The FDA, in 2021, recognized how quickly it is moving forward this technological and medical sector.

Neuralink's transition to human trials marks a pivotal moment In the search for advanced brain-computer interfaces, and the world You will closely observe their developments and results.

Post a Comment